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As our understanding of the nature and prevalence of post‐coronavirus disease
2019 (COVID‐19) syndrome (PCS) is increasing, a measure of the impact of
COVID‐19 could provide valuable insights into patients' perceptions in clinical
trials and epidemiological studies as well as routine clinical practice. To evaluate
the clinical usefulness and psychometric properties of the COVID‐19 Yorkshire
Rehabilitation Scale (C19‐YRS) in patients with PCS, a prospective, observational
study of 187 consecutive patients attending a post‐COVID‐19 rehabilitation clinic
was conducted. The C19‐YRS was used to record patients' symptoms, functioning,
and disability. A global health question was used to measure the overall impact of
PCS on health. Classical psychometric methods (data quality, scaling assumptions,
targeting, reliability, and validity) were used to assess the C19‐YRS. For the total
group, missing data were low, scaling and targeting assumptions were satisfied, and
internal consistency was high (Cronbach's α = 0.891). Relationships between the
overall perception of health and patients' reports of symptoms, functioning, and
disability demonstrated good concordance. This is the first study to examine the
psychometric properties of an outcome measure in patients with PCS. In this
sample of patients, the C19‐YRS was clinically useful and satisfied standard psy-
chometric criteria, providing preliminary evidence of its suitability as a measure
of PCS.
K E YWORD S
long COVID, Patient Reported Outcome Measure (PROM), post‐COVID‐19 symptoms,
psychometrics, SARS CoV‐2
J Med Virol. 2021;1–8. wileyonlinelibrary.com/journal/jmv | 1
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2021 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC
Rory J. O'Connor: LeedsADRM@twitter.com.
1 | INTRODUCTION
The medium and long‐term problems experienced by survivors of
coronavirus disease 2019 (COVID‐19) are emerging, with over one
million people in the UK who contracted COVID‐19 reporting
symptoms and functional problems more than 4 weeks after onset of
the acute illness.1 Almost 700 000 people report ongoing impact on
their health and functioning more than 12 weeks after the acute
infection, and this combination of symptoms and functional difficul-
ties is recognized as a new syndrome called “Long COVID” (LC) or
post‐COVID‐19 syndrome (PCS).1 The most common symptoms
include fatigue, breathlessness, pain, anxiety, and cognitive impair-
ment, but there are over 200 reported symptoms affecting 10 organ
systems.2 One study following 143 individuals seven weeks post-
discharge found 53% of patients reported fatigue, 43% breath-
lessness, and 27% joint pain.2 A substantial number of people report
limitations with their activities of daily living, with almost 130 000
patients stating that these limitations are severe.3 Given the novelty
and uniqueness of the syndrome, it is unsurprising that standardized
assessments of functioning, disability, and health are lacking. While
generic assessments are available, these have been shown to lack
responsiveness or be useful only for discriminative purposes.4,5
The long‐term symptoms of COVID‐19 might be predicted from
the previous coronavirus outbreaks in 2002 and 2012—Severe Acute
Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome
(MERS), respectively. Our meta‐analysis of follow‐up studies de-
monstrated that 25% of hospitalized survivors of SARS and MERS
experienced reduced lung function and lower exercise capacity
6 months postdischarge.6 One year on, posttraumatic stress disorder
(PTSD), depression, anxiety, and reduced quality of life were ob-
served. Preliminary research suggests that the impact of COVID‐19
infection is similar.7 Five studies in our metanalysis included the
Medical OutcomesTrust Short‐Form 36‐item generic health outcome
measure (SF‐36) as part of a basket of measures to try to determine
health outcomes after the acute infection. The breadth of long‐term
symptoms in patients affected by the previous SARS outbreaks, and
the emerging evidence of the long‐term impact of COVID‐19, means
that a single, generic health outcome measure, or indeed a basket of
measures, will be adequate to capture the breadth of these symp-
toms in a succinct way that is acceptable to patients and clinicians.
Furthermore, the responsiveness of the SF‐36 in detecting clinical
change when it occurred was small, limiting the utility of this measure
in measuring the effect of an intervention.
Using symptoms and functional difficulties of PCS that were being
reported by survivors of acute COVID‐19 infection and the healthcare
professionals involved in their care from across the clinical sites in the
Yorkshire region,7 we developed a condition‐specific measure for PCS.
The COVID‐19 Yorkshire Rehabilitation Scale (C19‐YRS) is a 22‐item
patient‐reported outcome measure designed to evaluate the long‐term
impact of COVID‐19 across the domains of Activities and Participation of
the International Classification of Functioning, Disability, and Health and
evaluate the impact of PCS rehabilitation.8 The C19‐YRS now includes
clinician‐completed, self‐report, and digital versions.3 Content validity of
the C19‐YRS has been demonstrated,7 and the C19‐YRS is now used in
the UK's first specialist PCS community rehabilitation service and 26
other National Health Service (NHS) PCS services in the UK.9
This article describes the first stage in establishing the initial psy-
chometric properties of the C19‐YRS as an outcome measure for PCS
using classical test theory.10 Its ongoing development will investigate
and address any problems with its psychometric properties using Item
Response Theory (specifically, Rasch analysis).11 This will explore the
presence of differential item functioning, local dependency of items, and
will examine unidimensionality and the YRS' responsiveness.
2 | METHODS AND DESIGN
This study was a prospective, observational study, and psychometric
analysis of data captured from long COVID patients using the C19‐YRS
questionnaire. Long COVID patients were recruited from a community‐
based Long COVID clinic within one of the UK's largest metropolitan
areas. Data were collected in the service as part of routine clinical
evaluation and ethical approval was obtained for the secondary analysis
of anonymized data collected for the primary clinical purpose, which had
been completed. A favorable ethical opinion was received from the
University of Leeds School of Medicine Research Ethics Committee in
January 2021 (reference MREC 20‐041—Secondary analysis of
C19‐YRS (COVID‐19 Yorkshire Rehabilitation Scale) data collected for
recording Long COVID symptoms and functional disability).
2.1 | Participants and recruitment
Data were collected from patients attending a community‐based PCS
rehabilitation service covering the Leeds City Region, a mixed urban and
rural district in the North of England with a population of approximately
850 000 people, which includes areas of significant social deprivation.
Patients were referred by their General Practitioner (GP), Community
Matron, or Respiratory Physiotherapy team to a PCS Community
Rehabilitation Service and completed a self‐report C19‐YRS as part of
initial triage. Initial eligibility was decided using the inclusion criteria. To
participate, each participant met the criteria stated:
2.1.1 | Inclusion criteria
• Patients are referred into the Long COVID Community
Rehabilitation Service by their GP, Community Matron, or
Respiratory Physiotherapy team to a PCS Community Re-
habilitation Service (this includes young people aged 16 and
above). A positive antigen or antibody test was not required
within the eligibility criteria as routine testing was not available at
the time of commencement of data collection.
• Ability to complete a self‐report C19‐YRS as part of initial triage.
Although literacy and language ability were not initially screened
unless highlighted by the referrer, support to complete the C19‐
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YRS form was provided where necessary by a family member or
carer, clinician, researcher, or a proprietary translation service
used by the clinical service.
• Willing and able to consent for data to be used anonymously for
research and/or service evaluation purposes. Consent was gathered
via the first page of the C19‐YRS form and did not affect a patient's
access to treatment. Data are already collected in the service as part
of routine initial evaluation to form a functional baseline and are
documented in the patient's electronic clinical notes.
2.1.2 | Exclusion criteria
• Inability to consent
2.2 | The C19‐YRS
The C19‐YRS consists of 22 items with each item rated on an
11‐point numerical rating scale from 0 (none of this symptom) to
10 (extremely severe level or impact). The C19‐YRS is divided into
four subscales (range of total score for each subscale): symptom
severity score (0–100), functional disability score (0–50), addi-
tional symptoms (0–60), and overall health (0–10). The C19‐YRS
can be freely obtained under license from the University of Leeds
(https://licensing.leeds.ac.uk/product/c19-yrs-covid-19-yorkshire-
rehabilitation-scale).
At triage, the C19‐YRS was completed independently by each
patient or, if the patient preferred, by a clinical researcher (an allied
health professional seconded into a research position, who was
involved in the initial assessment pathway) or a member of the
clinical team via telephone. Patients' family members or carers were
permitted to help complete the responses. On return of the C19‐
YRS, the clinical researchers transferred the data from each com-
pleted C19‐YRS to an Excel spreadsheet. The data were fully
anonymized, but details such as sex and age (not the date of birth)
were included. The full process is illustrated in Figure 1. Anonymity
was ensured by linking patient identifiable details to ID numbers on
one Excel sheet, and full C19‐YRS data sets on another. Only the ID
numbers linked the two documents, which were removed before
statistical team input.
It was not felt by the research team that formal training was required
before contacting patients (to organize the provision of the C19‐YRS) nor
completing the measure via the phone, as it is possible to read questions
verbatim from the C19‐YRS. A standard operating procedure and tele-
phone script were agreed upon, including allowing questions to be re-
peated for clarification with prompts provided for scale grading.
2.3 | Data analysis
Descriptive statistics are presented as an arithmetic mean and SD, or
median and interquartile range as appropriate. Absolute and relative
frequencies as appropriate for demographic and categorical variables
on the C19‐YRS are presented. Analyses were carried out using IBM
SPSS (Statistics 26, Release 26.0.0.0, 64‐bit edition, IBM Corp.). Four
psychometric analyses (data quality, scaling assumptions, targeting,
and reliability) were undertaken.
F IGURE 1 Flow chart illustrating patient recruitment and
preparation of data for research purposes. C19‐YRS, COVID‐19
Yorkshire Rehabilitation Scale; GP, General Practitioner
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2.4 | Data quality
Data quality concerns the extent to which a scale can be adminis-
tered successfully in the target sample. The C19‐YRS data were ex-
amined for percentage missing items and the percentage of the
sample for whom total scores could be calculated. For responders
with missing items, imputed scores were not used.12
2.5 | Scaling assumptions
Tests of scaling assumptions examine whether it is legitimate to sum item
scores to generate scale scores. In order for a set of items to be legiti-
mately summed to form a total score, a series of criteria should be sa-
tisfied.13–15 We tested the C19‐YRS against these criteria, which are:
Items should be roughly parallel, that is, measure at the same
point on the scale and have similar variance, otherwise they do
not contribute equally to the variance of the total score.16
A set of items is considered parallel when their item response
option frequency distributions and their item mean scores and
standard deviations are roughly similar.14
Items should measure the same underlying construct, otherwise, it
is not appropriate to combine them to generate a total score.11
A set of items is considered to be measuring the same construct
when each item's corrected item‐total correlation, which is the
correlation between each item and the total score computed
from the remaining items in that scale, exceeds 0.30.16
Items in the scale should contain a similar proportion of in-
formation concerning the construct being measured. This cri-
terion is considered satisfied if the corrected item‐total
correlations exceed 0.30.17
2.6 | Targeting
Targeting refers to the match between the distribution of health
problems in the sample and the range of health problems measured
by the scale. The better this match, the greater the potential for
precise measurement. Targeting was evaluated by examining floor
and ceiling effects, score distributions, and skewness statistics. Floor
effects are the percentage of patients scoring 10 (most severe impact
of symptom) and ceiling effects are the percentage of patients
scoring zero (symptom not present). It is recommended that floor and
ceiling effects should be less than 20% each on each item.18
2.7 | Reliability
Reliability describes the extent to which scale scores are free from
random error. Scales should generate reliable estimates of the con-
struct being measured (internal consistency). Cronbach's α coefficient
was used to determine this criterion.19 Although a range of minimum
values has been suggested, it is widely accepted that Cronbach's α
should exceed 0.80 for group comparison studies.15
3 | RESULTS
3.1 | Sample characteristics
Data for the analyses were obtained from 188 consecutive assess-
ments of PCS patients. Patient details are given inTable 1. One patient
was removed from the analyses because a significant number of an-
swers were missing, presumed to be an oversight of the respondent, or
due to symptoms impacting on the ability to complete the scale in full.
Follow‐up contact was not made with patients unless an answer to the
“overall health” question was suspected to be erroneously scored
(i.e., scoring their health higher post‐COVID than pre‐COVID).
Overall, 10% (n = 19) of the sample required telephone support
from the AHP researcher or clinical team to complete the C19‐YRS
due to a variety of factors (lack of digital access/digital literacy, cog-
nitive impairment or fatigue levels, or a wish to quicken registration
time by completing immediately). The length of time to administer the
C19‐YRS by telephone with researchers was 30min. It is unknown
how long it took patients to complete independently at home; how-
ever, subsequent Patient and Public Involvement work demonstrated
that it could be completed independently also within 30min.
Patients' scores on the C19‐YRS sub‐scales are presented in
Table 2. Fatigue was the most common complaint, with 97.3% of
patients reporting fatigue of varying severity, followed by the onset of
pain, which was not present before COVID‐19 was contracted
(94.3%). The most common new pain was muscle pain, which affected
70% of patients, followed by headache (67%), chest (64%), and joint
pain (59%). Approximately one‐third of patients also experienced new
pain in their abdominal or other regions. Mental health problems were
reported by 41% of patients, with 17% of these patients reporting
respiratory or cardiac comorbidity. Respiratory or cardiac health issues,
or both, were reported by 37% of patients. Swallowing, incontinence,
skin rash, and fever were troublesome for very few the respondents.
3.2 | Data quality
Missing data for items were low (range 0.5%–19.8%). Subscale scores
could be calculated for 67% of patients reporting symptom severity,
82% of patients reporting functional disability, 83% of patients re-
porting additional symptoms, and 98% of patients reporting overall
health. Details of scores are given in Table 2.
3.3 | Scaling assumptions
Item response option frequency distributions were symmetric. Item
means and standard deviations were similar indicating that they were
roughly parallel (Table 3), although there was a greater range in
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symptom severity. Corrected item‐total correlations exceeded 0.30
for all items except swallowing (0.24), incontinence (0.28), and skin
rash (0.14), indicating that scaling assumptions were met for most
items, including fever (0.33).
3.4 | Targeting
Scores spanned the range of the scale on admission and discharge and
demonstrated good variability (Table 3). Results for some items demon-
strated notable floor effects, especially for swallowing (72.7%), skin rash
(66.8%), and fever (64.7%). There were no ceiling effects in any subscale.
3.5 | Reliability
Internal consistency of the overall C19‐YRS was good (Cronbach's
α = 0.891). Individual subscales also demonstrated good reliability.
Deletion of the items noted to have poor scaling assumptions and
targeting improved the reliability of the symptom severity subscale
(swallowing, incontinence removed; Cronbach's α 0.79–0.81) and the
additional symptoms subscale (fever, skin rash removed; Cronbach's
α 0.70–0.74). These items were infrequently endorsed by partici-
pants, with fewer than 10% of participants endorsing a score greater
than zero for any of these items, indicating that although bothersome
to a small number of patients, their contribution to the overall
measurement properties of the scale was limited.
The symptom severity, functional disability, and additional
symptoms sub‐scales correlated strongly with each other (Table 4),
indicating that the sub‐scales have a coherent internal structure. The
overall health scale also correlated strongly with the other three
subscales. As this is a more generic question of health status, this
provides preliminary evidence of construct validity.
TABLE 1 Patient demographics
Non‐
hospitalized Hospitalized
Total no (%) 84% (n = 157) 15% (n = 28) ICU
5.4% (n = 10)
Age: mean (SD) 47.1
(SD 13.74)
51.9 (SD 12.83)





18 (16); 12 (5–33)
Sex (%)
Female 66% (n = 104) 43% (n = 12)
Male 34% (n = 54) 57% (n = 16)
Ethnicity (%)
White‐British, Northern
Irish, Rep of Ireland
80% (n = 126) 60.6% (n = 18)
Asian/British Asian 6% (n = 10) 18% (n = 5)
Black – Black British,
African, Black African
2% (n = 3) 7.2% (n = 2)
Mixed – Asian, Mixed White
and Black African, Mixed
White and Black
Caribbean
2.5% (n = 4) 0
Other – Undefined White,
European or British
8% (n = 12) 7.1% (n = 2)
Arab 1.3% (n = 2) 1% (n = 3.6)
Occupation (%)
Healthcare workers 30% (n = 47) 21% (n = 6)
Non‐healthcare 70% (n = 111) 79% (n = 22)
Impact on vocation (%)
Reduced hours/
adjusted work
17% (n = 26) 4% (n = 1)
Off‐sick 19% (n = 30) 57% (n = 16)
No effect 64% (n = 100) 39% (n = 11)
Symptoms in PCS (%)
Fatigue 92% (n = 145) 89% (n = 25)
Noisy breathing 41% (n = 65) 54% (n = 15)
Cough/throat sensitivity 58% (n = 91) 68% (n = 19)
Pain (%)
Chest pain 65% (n = 103) 61% (n = 17)
Muscle pain 70% (n = 111) 68% (n = 19)
Joint pain 59% (n = 93) 61% (n = 17)
Abdominal pain 31% (n = 49) 36% (n = 10)
Headache 70% (n = 110) 54% (n = 15)






Bowel control 16% (n = 25) 29% (n = 8)
Bladder control 18% (n = 28) 36% (n = 10)
Cognition difficulty (%)
Planning 56% (n = 88) 64% (n = 18)
Short term memory 70% (n = 111) 75% (n = 21)




Abbreviations: COVID‐19, coronavirus disease 2019; ICU, intensive care
unit; PCS, post‐COVID‐19 syndrome; SD, standard deviation.
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4 | DISCUSSION
The C19‐YRS was developed by a rehabilitation research team as a
disease‐specific patient‐based measure of the impact of COVID‐19 in-
fection as part of the establishment of clinical service to meet the needs
of patients recovering from the effects of the infection.20,21 The scale has
been used successfully to gather symptom severity and functional impact
and monitor progress in PCS, and is recommended by the UK's National
Health Service England,22 and the National Institute for Health and Care
Excellence (NICE).23 However, it is recognized that the C19‐YRS requires
further iterations for development and refinement, and wider demo-
graphic data to establish more of the determinants of the impact of
COVID‐19 infection on individuals.
Many studies of rehabilitation in PCS have used generic mea-
sures of health outcomes. Conceptually, however, there are good
arguments for making a PCS‐specific scale given that many re-
habilitation strategies aim to ameliorate the specific impairments
associated with PCS. We examined this self‐report version of the
C19‐YRS, initially designed for use with patients discharged from
acute hospital settings, then modified to suit both hospitalized and
TABLE 2 Patients' scores on the C19‐YRS sub‐scales
Subscale (scale range) Valid scores Mean (SD) Median (IQR) Score range Skewness
Symptom severity (0–100) 125 42.7 (0.36) 40.0 (31.0–54.5) 10–81 0.232
Functional disability (0–50) 153 18.8 (10.7) 17 (11.0–26.5) 0–48 0.535
Additional symptoms (0–60) 155 18.8 (10.8) 18.0 (10.0–28.0) 0–48 0.246
Overall health (0–10) 183 4.6 (2.1) 4.0 (3.0–6.0) 0–10 0.265
Note: Data are only presented for patients with complete subscale scores.
Abbreviations: C19‐YRS, COVID‐19 Yorkshire Rehabilitation Scale; COVID‐19, coronavirus disease 2019; IQR, interquartile range; SD, standard deviation.










Item means: range 0.9–7.2 3.5–4.9 3.5–4.6 4.0–4.9
Item SD: range 1.9–3.3 0.3–1.5 1.1–1.6 0.8–1.1
Item‐total correlations 0.24–0.62 0.39–0.67 0.16–0.62
Targeting
Missing data (%): range 0.5–19.8 0.5–15.5 5.9–12.3 2.1
Floor effects (%): range 5.3–72.7 16.4–61.0 15.0–66.8 2.1
Ceiling effects (%): range 0.0–9.6 0.5–4.8 0.0–10.2 1.1
Reliability
Cronbach's α 0.79 0.79 0.70
Abbreviations: C19‐YRS, COVID‐19 Yorkshire Rehabilitation Scale; COVID‐19, coronavirus disease 2019; SD, standard deviation.
TABLE 4 Correlation of the C19‐YRS
sub‐scales with the overall health scale*
Pearson's correlation (significance) across subscales
Symptom severity Functional disability Additional symptoms
Overall health −0.322 (<0.001) −0.352 (<0.001) −0.208 (0.010)
Additional symptoms 0.657 (<0.001) 0.515 (<0.001)
Functional disability 0.772 (<0.001)
Abbreviations: C19‐YRS, COVID‐19 Yorkshire Rehabilitation Scale; COVID‐19, coronavirus
disease 2019.
*Overall health was reversed scored compared to item severity, so that an overall health score of “10”
reflected the best possible health, in contrast to item severity where “10” reflected the worst possible
severity of the symptom.
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nonhospitalized patients, to determine the stability of the psycho-
metric properties and its potential as a measure of PCS. In this first
round of preliminary testing, our results provide evidence for that
potential. In the group studied, evidence was found for data quality,
scaling assumptions, targeting, and reliability. The findings from this
study provide useful information and illustrate the potential of the
C19‐YRS to achieve the necessary standards for highly accurate,
psychometrically robust measurement.
This study has limitations. First, it is a study from a single clinical
site and includes patients with a diverse range of experiences of
acute COVID‐19 infection. While there is some evidence that small
samples provide useful reliability and validity estimates,24 we
recognize that our sample is relatively small at present. Nevertheless,
our patient cohort is growing rapidly, and we aim to have in excess of
500 patients in our definitive psychometric analyses. Second, the
scale is self‐report and thus the extent to which it is applicable in
patients with severe fatigue or who have impairments affecting
communication remains to be determined. In this study, patients
could be provided with assistance to complete the questionnaire but
is recognized that patients may answer items in questionnaires dif-
ferently when the measures are administered by self‐completed
questionnaire compared to an interview by a member of staff, and
this may lead to a bias in the reporting of the scores.25 Third, we have
not studied test‐retest reliability. However, Cronbach's alpha is
considered to be a conservative reliability estimate, and test‐retest
reliability often over‐estimates reliability. The underpinning research
has been discussed by Nunnally26 and others.15,25,26
Despite these limitations, we are confident that the C19‐YRS will
turn out to be a useful addition to current assessments of post‐
COVID‐19 in clinical studies, and could be used to complement
clinician‐rated measures of symptoms. Furthermore, the items in the
scale provide qualitative information to clinicians to assist in targeting
their clinical interventions to individuals' needs. It has advantages over
other approaches, as it may be used in any setting, does not require an
external rater, and is not laboratory‐based or require special equip-
ment. Most importantly it measures patients' perspectives.27
4.1 | Further research
In future validations, as cases accumulate, the researcher will seek
outpatients whose circumstances and perspectives provide a contrast
to those already included to achieve maximum variety in clinical,
social, ethnic, and personal circumstances and health/digital literacy.
Subsequent psychometric testing will use Rasch analysis to de-
termine whether the scale meets the fundamental axioms that define
scientific measurement and permit the transformation of raw
(ordinal) scores to interval level measurement.11 Further evaluations
will examine the short‐ and long‐term responsiveness of the scale to
changes in symptom severity and the overall impact of rehabilitation
on PCS. This will also determine the minimal clinical important dif-
ference of the scale that correlates to clinical improvement or de-
terioration of the condition reported by patients.
5 | CONCLUSION
This is the first study to examine the psychometric properties of a
PCS‐specific outcome measure that captures and evaluates the
symptoms experienced by patients. In this sample of patients, the
C19‐YRS was clinically useful and satisfied standard psychometric
criteria. The C19‐YRS shows good internal consistency, and scaling
and targeting assumptions were satisfied. This provides preliminary
evidence that the C19‐YRS outcome measure of PCS patients has
satisfactory psychometric properties.
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